Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.
The effects of steady-state faldaprevir on the safety, pharmacokinetics, and pharmacodynamics of steady-state methadone and buprenorphine-naloxone were assessed in 34 healthy male and female subjects receiving stable addiction management therapy. Subjects continued receiving a stable oral dose of either methadone (up to a maximum dose of 180 mg per day) or buprenorphine-naloxone (up to a maximum dose of 24 mg-6 mg per day) and also received oral faldaprevir (240 mg) once daily (QD) for 8 days following a 480-mg loading dose. Serial blood samples were taken for pharmacokinetic analysis. The pharmacodynamics of the opioid maintenance regimens were evaluated by the objective and subjective opioid withdrawal scales. Coadministration of faldaprevir with methadone or buprenorphine-naloxone resulted in geometric mean ratios for the steady-state area under the concentration-time curve from 0 to 24 h (AUC(0-24,ss)), the steady-state maximum concentration of the drug in plasma (C(max,ss)), and the steady-state concentration of the drug in plasma at 24 h (C(24,ss)) of 0.92 to 1.18 for (R)-methadone, (S)-methadone, buprenorphine, norbuprenorphine, and naloxone, with 90% confidence intervals including, or very close to including, 1.00 (no effect), suggesting a limited overall effect of faldaprevir. Although individual data showed moderate variability in the exposures between subjects and treatments, there was no evidence of symptoms of opiate overdose or withdrawal either during the coadministration of faldaprevir with methadone or buprenorphine-naloxone or after faldaprevir dosing was stopped. Similar faldaprevir exposures were observed in the methadone- and buprenorphine-naloxone-treated subjects. In conclusion, faldaprevir at 240 mg QD can be coadministered with methadone or buprenorphine-naloxone without dose adjustment, although given the relatively narrow therapeutic windows of these agents, monitoring for opiate overdose and withdrawal may still be appropriate. (This study has been registered at ClinicalTrials.gov under registration no. NCT01637922.).
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
David
D
Joseph
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
Michael J
MJ
Schobelock
Atlanta Center for Medical Research, Atlanta, Georgia, USA.
Robert R
RR
Riesenberg
Vince & Associates Clinical Research, Atlanta, Georgia, USA.
Bradley D
BD
Vince
CRI Lifetree, Salt Lake City, Utah, USA.
Lynn R
LR
Webster
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
Abidemi
A
Adeniji
Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington, Ontario, Canada.
Mabrouk
M
Elgadi
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA fenglei.huang@boehringer-ingelheim.com.
Fenglei
F
Huang
D000284:Administration, Oral; D000328:Adult; D000621:Aminoisobutyric Acids; D002047:Buprenorphine / Q000031:analogs & derivatives / Q000097:blood; D000069479:Buprenorphine, Naloxone Drug Combination / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives; D008297:Male; D008691:Methadone / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged; D009842:Oligopeptides / Q000493:pharmacokinetics* / Q000494:pharmacology; D011392:Proline / Q000031:analogs & derivatives; D011804:Quinolines; D013375:Substance Withdrawal Syndrome; D019966:Substance-Related Disorders / Q000188:drug therapy; D013844:Thiazoles / Q000493:pharmacokinetics* / Q000494:pharmacology; D055815:Young Adult
D000621:Aminoisobutyric Acids; D000069479:Buprenorphine, Naloxone Drug Combination; D009842:Oligopeptides; D011804:Quinolines; D013844:Thiazoles; D002047:Buprenorphine; C043585:norbuprenorphine; C552340:faldaprevir; D011392:Proline; D007930:Leucine; D008691:Methadone